Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Mirum Pharmaceuticals ( (MIRM) ) is now available.
On May 29, 2025, Mirum Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class III directors to serve until 2028, ratified Ernst & Young LLP as the independent public accounting firm for 2025, and approved executive compensation, indicating continued support for the company’s leadership and strategic direction.
The most recent analyst rating on (MIRM) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
Mirum Pharmaceuticals shows strong revenue growth and positive regulatory developments, as noted in the earnings call, which contributed positively to the score. However, financial performance challenges such as negative profitability and high leverage, along with a poor valuation score due to the negative P/E ratio, weigh heavily on the overall score. Technical analysis provides a neutral influence, reflecting moderate market conditions. The overall score reflects the balance between growth potential and significant financial and valuation risks.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for rare and debilitating liver diseases.
Average Trading Volume: 446,241
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B
Learn more about MIRM stock on TipRanks’ Stock Analysis page.